
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is experiencing strong revenue growth, driven by traditional year-end buy-ups and continued conversion to subscription-based arrangements. Their strong gross margins and ability to manage costs have resulted in EBITDA margins of 37%, leading to a significant EPS beat. While 2026 revenue guidance has been lowered due to uncertainty surrounding Most Favored Nation pricing and shorter contract durations, the company has a strong track record of managing costs and a solid customer base of pharmaceutical clients. Their AI capabilities provide potential for further growth and cost savings, and the company has a built-in operating leverage with their current headcount. Overall, the company's strong financial performance and potential for future growth make it a solid investment opportunity with a target price of $17.
Bears say
OptimizeRx is facing challenges with slowing revenue growth and decreased visibility due to uncertainties brought on by "most favored nation" pricing headwinds from the Trump Administration. Furthermore, the company's reliance on a few large pharmaceutical manufacturers for a significant portion of its sales puts it at risk if any of those partnerships were to end. The company has also had a history of needing to raise capital in order to sustain positive cash flow, which could dilute existing shareholders and hinder its ability to aggressively pursue sales and marketing efforts.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares